cdmo.directory
← Compare landing

Merck KGaA vs ProBio

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryMerck KGaAProBio
SummaryRecent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea.ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
ServicesData not yet provided.
  • Protein Engineering
  • In Vitro Pharmacology
  • Bioanalysis
  • Immunogenicity Assays (ADA / NAb)
  • Flow Cytometry Services
  • Analytical Method Development & Validation
  • ICH Stability Studies
ModalitiesData not yet provided.
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • AAV / Viral Vector Platform
Development capabilitiesData not yet provided.Data not yet provided.
Manufacturing capabilitiesData not yet provided.Data not yet provided.
Locations
  • Daejeon Bioprocessing Center, Daejeon, South Korea
  • United States, United States
  • Netherlands, Netherlands
  • South Korea, South Korea
  • Hong Kong, Hong Kong, China
  • Shanghai, Shanghai, China
  • Nanjing, Nanjing, China
CertificationsData not yet provided.
  • FDA · Identifier: US Food and Drug Administration
  • EMA · Identifier: European Medicines Agency
  • NMPA · Identifier: National Medical Products Administration

Find similar companies

Merck KGaA alternatives · ProBio alternatives

Markdown mirror: /compare/merck-kgaa/probio.md